Tagged with R

Europe Obesity is pharma’s new El Dorado. Following the spectacular market success and sky-high sales projections of next-generation obesity treatments, many actors – both large and small – are looking to carve out a slice of this huge growth market. Those who made a bet on obesity years in advance are…

India Dr Arunish Chawla details the policy strategies underlying the explosive prospected growth of India’s pharmaceutical sector to USD 120-150 billion by 2030, including rigorous adherence to international quality standards. Highlighting regulatory reforms and India’s nuanced stance on intellectual property, Dr Chawla envisions India as a balanced player in healthcare across…

Portugal João Rito introduces Bluebio Alliance, a Portuguese association focusing on bio-based marine resources and their sustainable utilisation. Rito’s work involves extensive collaboration across sectors, including pharmaceuticals, to promote the blue bioeconomy, and he emphasises the importance of sustainable practices in harnessing marine bioresources, such as fish, seaweed, and coral, for…

Portugal Boehringer Ingelheim has a 60-year history in Portugal and, despite challenges in terms of market access and reimbursement delays, remains fully committed to providing innovative healthcare solutions in the country. General Manager Sandra Marques outlines how the firm has established itself as a major player in Portugal’s prescription retail market,…

Portugal From software development to sales and consultancy, Alexandre Leiria today heads up the Life Sciences, Healthcare, and Manufacturing arm of digital-focused consultancy Capgemini in Portugal. He discusses Capgemini’s role in advancing digital transformation in the Portuguese healthcare sector. Despite progress, challenges remain, such as the need for further investments and…

India Pharmexcil’s Ravi Uday Bhaskar discusses how Indian pharma is rebuilding global confidence in its exports via a focus on quality, expanding into high-potential new markets like those in Latin America, and adapting to global trends like the US Inflation Reduction Act and changing European regulations.   Despite global economic challenges,…

Portugal Dr João Filipe Raposo outlines the importance of a collaborative, multidisciplinary approach to diabetes care management, an approach embodied by the APDP – Diabetes Portugal. He also touches on the APDP’s unique patient-centric model and the digital future of diabetes care.   I am optimistic that diabetes care will improve.…

Portugal Nuno Sousa details the development of Portugal’s clinical research ecosystem, highlighting the creation of the Clinical Academic Center of Braga (2CA-Braga) and its evolution. He emphasises the necessity of building on 2CA Braga’s successes to create a network of strong research centres across Portugal, making the country a more competitive…

Europe The European Medicines Agency (EMA) recommended 77 drugs for marketing authorisation in 2023, including 39 new active substances, coming up behind the FDA’s record 55 new drug approvals last year. Cancer led the roster of EMA green lights with 25 authorisations, including nine therapies the agency has discerned as major…

LatAm A roundup of some of the latest stories from Latin American pharma and healthcare, including Sanfer’s acquisition of Columbia-based injectables manufacturer Vitalis; medicine shortages in Colombia, and Chile’s move towards universal primary health coverage with support from the World Bank.   ACON Investments Signs Definitive Agreement to Sell Vitalis to…

Global Every year, the world’s top business and political leaders converge on the ski village of Davos, Switzerland for the World Economic Forum meeting. Read on for some of the key themes discussed at this year’s conference, which stand to shape the healthcare and life sciences industry in the coming year.…

China Two leading regional pharma executives, from Eli Lilly and Boehringer Ingelheim respectively have recently moved to head up China operations; perhaps a sign that despite recent geopolitical tensions, multinational biopharma is again/still betting on the country. With innovation-friendly healthcare reforms in place, as well as measures to encourage foreign investment,…